GENESIS THERAPEUTICS, INC.

Profile

Company Names

GENESIS THERAPEUTICS, INC.

Addresses

1440 CHAPIN AVE, SUITE 385, BURLINGAME, CA 94010

1860 EL CAMINO REAL, SUITE 400, BURLINGAME, CA 94010

Phone Numbers

203-615-4567

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2019

State Incorporated:

DELAWARE

Total Amount Raised:

$297,437,884.00

Number of Funding Rounds:

3
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
3
2023-08-10 
$224,025,681.00 
$224,025,681.00 
$0.00 
Equity 
2
2022-06-22 
$23,894,572.00 
$23,894,572.00 
$0.00 
 
1
2020-11-24 
$49,517,631.00 
INDEFINITE 
INDEFINITE 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
LEONARD 
 
BELL 
DIRECTOR
GENESIS THERAPEUTICS, INC.
STEPHEN 
 
DANN 
EXECUTIVE OFFICER
GENESIS THERAPEUTICS, INC.   |  MEDICAL REALITIES, INC.
EVAN 
 
FEINBERG 
EXECUTIVE OFFICER, DIRECTOR
BELEZA.COM LTD.   |  GETNINJAS HOLDINGS LTD.   |  AVENIDA INC.   |  GENESIS THERAPEUTICS, INC.
KRIS 
 
JENNER 
DIRECTOR
ROCK SPRINGS CAPITAL FUND LP   |  ROCK SPRINGS CAPITAL OFFSHORE FUND LP   |  FOUR PINES OFFSHORE FUND LP   |  FOUR PINES ONSHORE FUND LP   |  GENESIS THERAPEUTICS, INC.
WILLIAM 
 
MCCARTHY 
EXECUTIVE OFFICER
WILD PLANET FOODS INC   |  REHABILITATION + COMMUNITY PROVIDERS SERVICES ORGANIZATION, INC.   |  OCIENT INC.   |  OCIENT HOLDINGS LLC   |  GENESIS THERAPEUTICS, INC.
VIJAY 
 
PANDE 
DIRECTOR
APEEL TECHNOLOGY, INC.   |  FREENOME HOLDINGS, INC.   |  ASIMOV INC.   |  IGNITE BIOSCIENCES, INC.   |  NAUTILUS BIOTECHNOLOGY, INC.   |  INSITRO, INC.   |  NAUTILUS BIOTECHNOLOGY, INC.   |  SCRIBE THERAPEUTICS, INC.   |  ARTEMYS INC.   |  NOBELL FOODS, INC.   |  GENESIS THERAPEUTICS, INC.   |  BIOAGE LABS, INC.
PEPTIBOON 
 
PRASIT 
DIRECTOR, EXECUTIVE OFFICER
GENESIS THERAPEUTICS, INC.
BENJAMIN 
 
SKLAROFF 
EXECUTIVE OFFICER
GENESIS THERAPEUTICS, INC.
NICHOLAS 
 
STOCK 
EXECUTIVE OFFICER
GENESIS THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2023-08-25
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2023-08-10 
2022-12-23
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2022-06-22 
2020-12-09
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-11-24 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#